2025-11-06 07:28:44
Latest Post
Avalon Technologies Ltd Q2FY26 consolidated net profit at Rs. 24.97 crores
CyberTech Systems and Software Ltd Q2 FY2025-26 consolidated profit at Rs. 8.65 crores
Piramal Pharma Ltd consolidated Q2FY26 loss at Rs. 99.22 crores
Syngene International Ltd Q2FY26 consolidated PAT declines to Rs. 67.1 crores
Magellanic Cloud Ltd Q2 FY2026 consolidated PAT at Rs. 27.61 crores
Stock Report
Gland Pharma Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 183.68 crores
Posted On : 2025-11-03 22:11:29( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended September 30, 2025.
Financial Results (Q2 FY2026) - QoQ Comparison
The company has reported total income of Rs. 1571.037 crores during the period ended September 30, 2025 as compared to Rs. 1563.149 crores during the period ended June 30, 2025.
The company has posted net profit / (loss) of Rs. 183.684 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs. 215.482 crores for the period ended June 30, 2025.
The company has reported EPS of Rs. 11.15 for the period ended September 30, 2025 as compared to Rs. 13.08 for the period ended June 30, 2025.
| Financials | Q2 FY2026 | Q1 FY2026 | % Change |
| Total Income | ₹ 1571.037 crs | ₹1563.149 crs |  0.50% |
| Net Profit | ₹183.684 crs | ₹215.482 crs |  -14.76% |
| EPS | ₹11.15 | ₹13.08 | -14.76% |
Financial Results (Q2 FY2026) - YoY Comparison
The company has reported total income of Rs. 1571.037 crores during the period ended September 30, 2025 as compared to Rs.1465.492 crores during the period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.183.684 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs.163.532 crores for the period ended September 30, 2024.
The company has reported EPS of Rs.11.15 for the period ended September 30, 2025 as compared to Rs.9.93 for the period ended September 30, 2024.
| Financials | Q2 FY2026 | Q2 FY2025 | % Change |
| Total Income | ₹ 1571.037 crs | ₹1465.492 crs | 7.20% |
| Net Profit | ₹183.684 crs | ₹163.532 crs | 12.32% |
| EPS | ₹11.15 | ₹9.93 | 12.29% |
Financial Results (Half Year Ended FY2026) - YoY Comparison
The company has reported total income of Rs.3134.186 crores during the 6 Months period ended September 30, 2025 as compared to Rs.2918.628 crores during the 6 Months period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.399.166 crores for the 6 Months period ended September 30, 2025 as against net profit / (loss) of Rs.307.293 crores for the 6 Months period ended September 30, 2024.
The company has reported EPS of Rs.24.23 for the 6 Months period ended September 30, 2025 as compared to Rs.18.65 for the 6 Months period ended September 30, 2024.
| Financials | Half Year Ended FY2026 | Half Year Ended FY2025 | % Change |
| Total Income | ₹3134.186 crs | ₹2918.628 crs | 7.39% |
| Net Profit | ₹399.166 crs | ₹307.293 crs | 29.90% |
| EPS | ₹24.23 | ₹18.65 | 29.92% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 1972.15 as compared to the previous close of Rs. 1929.50. The total number of shares traded during the day was 14300 in over 1659 trades.
The stock hit an intraday high of Rs. 2030.00 and intraday low of 1925.00. The net turnover during the day was Rs. 28447457.00.
